Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Publication year range
1.
Haematologica ; 91(5): 703-6, 2006 May.
Article in English | MEDLINE | ID: mdl-16627252

ABSTRACT

In a prospective, open-label study, 25 patients with mild-to-moderate type 1 Gaucher's disease (GD1) were treated with miglustat (Zavesca), an oral glucosylceramide synthase inhibitor, over 12 months. Of the 25 patients, 10 were therapy-naïve and 15 had previously received enzyme replacement therapy (ERT). Clinical status, blood parameters, biomarkers, and organomegaly were assessed at baseline at 6 months and at 12 months. At 6 months the previously untreated patients showed a mean increase in hemoglobin of 0.77 g/dL, platelet counts improved or remaining stable, chitotriosidase and CCL18 decreased. These results were similar to those observed in 40 Spanish GD1 patients on ERT. Bone marrow infiltration cleared at 12 months. In the previously treated group, clinical and hematologic parameters and biomarkers were maintained/ improved at 12 months. Miglustat was well tolerated. The efficacy of miglustat treatment after 6 months was comparable to that of ERT.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , Gaucher Disease/drug therapy , 1-Deoxynojirimycin/administration & dosage , 1-Deoxynojirimycin/therapeutic use , Administration, Oral , Adult , Aged , Bone Marrow/pathology , Chemokines, CC/blood , Drug Administration Schedule , Female , Gaucher Disease/enzymology , Gaucher Disease/genetics , Genotype , Glucosylceramidase/therapeutic use , Glucosylceramides/biosynthesis , Glucosyltransferases/antagonists & inhibitors , Hexosaminidases/blood , Humans , Male , Middle Aged , Neuropsychological Tests , Quality of Life , Treatment Outcome
3.
Bol. Acad. Chil. Med ; (40): 173-179, 2003.
Article in Spanish | HISA - History of Health | ID: his-19427

ABSTRACT

La profesión médica en Chile es la que se ha constituido con más éxito en nuestra historia. Se constituyó en el corto espacio de medio siglo, más o menos entre 1833 y la década de 1870, cuando se funda la Sociedad Médica (1869), la Revista Médica de Chile (1872). Cuando digo exitoso me refiero a tres condiciones mínimas: una enseñanza sólidamente establecida que justificara reclamar el monopolio de la, profesión, un sistema jurídico que le reconociera ese monopolio, un cuerpo de profesionales organizado como tal y finalmente, quizás el más relevante, el valor que esa sociedad le da al servicio profesional. Estas condiciones de profesionalización exitosa nos conducen a instituciones claras: una Escuela de Medicina, un Estado que regula, un servicio y un mercado. Con bases más o menos precarias, estos cuatro pilares estaban en pie hacia 1870. Había pasado de ser un oficio tradicional empírico a una profesión moderna basada en ciencia. Cuando en la década de 1830 se planteó la necesidad de establecer un curso médico, contemplado en los programas del Instituto Nacional desde 1813, existía una regulación de la profesión y prácticamente nada más. Al contrario de los países sajones donde la profesión se constituyó desde el desarrollo interno de los empíricos anteriores, en Chile tuvo que crearse en contra de ellos por la calidad de su formación. Fueron los extranjeros, ya es una historia tan sabida, quienes aportaron el saber de la disciplina y en la década del 30 se hicieron cargo del protomedicato y de prestigiar la profesión dentro de una elite que no le otorgaba mayor valor ni a la ciencia, ni al campo ni al servicio. En 1833 confluyó la voluntad progresita del Gobierno con la disposición de estos médicos extranjeros, tampoco eran muchos, para formar el primer curso que contribuiría a desvanecer esa "preocupacxión vulgar" que había llevado al descrédito de la profesión en el país. De los cuatro profesores solo dos tenían estudios formales Blest y Sazié...(AU)


Subject(s)
Schools, Medical/history , Education, Medical/history , History of Medicine , Chile
4.
J Invest Dermatol ; 118(4): 639-44, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11918710

ABSTRACT

Cowden syndrome is an autosomal dominant genodermatosis, characterized by the presence of multiple hamartomas in the skin, breast, thyroid, gastrointestinal tract, central nervous system, and an increased risk in developing breast and thyroid carcinomas. Over 80 germline mutations of the tumor suppressor gene PTEN, on chromosome 10q23, have been reported in more than 100 unrelated patients and families; however, questions regarding distribution of the mutations in populations from different geographic areas, and phenotypic expression are still unclear. In this study the results are reported of mutation analysis of PTEN in 13 families from Spain and one family of Brazilian origin with Cowden syndrome. PTEN germline mutations were detected in nine of them (64%). Five mutations were located in exon 5, one in exon 6, two in exon 7, and one in exon 8. Four of the mutations were novel. In another case, an identical change had been previously reported as a somatic mutation in an endometrial carcinoma. In one family, the patient presented a de novo mutation, which was not detected in his parents. In five patients, the detection of the PTEN germline mutation confirmed their condition, even in the absence of sufficient criteria to make the clinical diagnosis of Cowden syndrome.


Subject(s)
Hamartoma Syndrome, Multiple/genetics , Phosphoric Monoester Hydrolases/genetics , Tumor Suppressor Proteins/genetics , Adolescent , Adult , Aged , Brazil , Child , Child, Preschool , Exons , Family Health , Female , Germ-Line Mutation , Humans , Male , Middle Aged , PTEN Phosphohydrolase , Pedigree , Spain
SELECTION OF CITATIONS
SEARCH DETAIL
...